ABVX
Abivax SA
NASDAQ · Healthcare · Biotechnology · FR
$87.49
−0.73%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- -15.5%
- Free cash flow
- -85.0%
- Operating cash flow
- -85.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +48.8%
- EPS
- +27.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- -84.8%
- EBIT
- -42.2%
- Net income
- -90.7%
- EPS
- -66.1%
- Free cash flow
- -0.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026